Hepatocyte Loss of TRMT61A Aggravates Liver Fibrosis by Driving ATF3‐Mediated Apoptosis and Macrophage Recruitment
Advanced Science · 2026-11-18
DOI: 10.1002/advs.78723 ↗At a glance
Journal article in Advanced Science, published online on 2026-11-18. Written by Xin Zhang and 11 co-authors. 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.
Abstract (original language)
Liver fibrosis is a common pathological consequence of chronic liver injury, but the hepatocyte‐intrinsic mechanisms that initiate fibrogenic remodeling of the hepatic microenvironment remain incompletely defined. Here, we identify the RNA methyltransferase TRMT61A as a hepatocyte protective factor that is reduced in human fibrotic liver tissues and in experimental mouse models of liver fibrosis. Hepatocyte‐specific deletion of Trmt61a was sufficient to trigger liver injury and progressive fibrosis, whereas restoration of enzymatically active TRMT61A restored m 1 A modification and ameliorated fibrosis. Mechanistically, Trmt61a deficiency activated the integrated stress response (ISR) marked by eIF2α phosphorylation and ATF3 induction, promoting hepatocyte apoptosis and CCL2 production. Transcriptomic and single‐cell analyses revealed profound remodeling of the hepatic immune microenvironment, characterized by loss of embryonically derived Kupffer cells and accumulation of CCR2‐positive monocyte‐derived macrophages with pro‐fibrotic inflammatory programs. Pharmacological CCR2/CCR5 blockade with cenicriviroc or hepatic Atf3 knockdown reduced macrophage infiltration and attenuated fibrosis in Trmt61a ‐deficient mice. These findings underscore the pivotal role of TRMT61A in regulating hepatocyte fate and remodeling the hepatic immune microenvironment during fibrosis progression, with the ISR–ATF3 axis serving as a central mechanistic hub. Restoring TRMT61A activity in hepatocytes thus represents a promising therapeutic strategy for preserving hepatocyte function and counteracting liver fibrosis.
Funding
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
Cite
APA
Zhang, X., Wang, J., Long, X., Hu, Z., Wo, L., Shao, Y., Liu, C., Yu, Q., Zhou, C., Chen, G., Wang, Q., & Zhao, Q. (2026). Hepatocyte Loss of TRMT61A Aggravates Liver Fibrosis by Driving ATF3‐Mediated Apoptosis and Macrophage Recruitment. Advanced Science. https://doi.org/10.1002/advs.78723
Vancouver
Zhang X, Wang J, Long X, Hu Z, Wo L, Shao Y, et al. Hepatocyte Loss of TRMT61A Aggravates Liver Fibrosis by Driving ATF3‐Mediated Apoptosis and Macrophage Recruitment. Advanced Science. 2026. doi:10.1002/advs.78723
BibTeX
@article{Zhang2026,
author = {Zhang, Xin and Wang, Jiao and Long, Xi‐Dai and Hu, Zhe‐Xuan and Wo, Lu‐Lu and Shao, Yan‐Fei and Liu, Chang and Yu, Qian‐Ru and Zhou, Ci‐Xiang and Chen, Guo‐Qiang and Wang, Qiuyu and Zhao, Qian},
title = {Hepatocyte Loss of TRMT61A Aggravates Liver Fibrosis by Driving ATF3‐Mediated Apoptosis and Macrophage Recruitment},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78723}
}
EUVIMED